ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "methotrexate (MTX) and rheumatoid arthritis"

  • Abstract Number: 597 • 2018 ACR/ARHP Annual Meeting

    Characteristics of Patients and Predictors of Composite Disease Activity Scores for Switching to Monotherapy Vs Continuing TNF Inhibitor and Methotrexate Combination Therapy in RA: A Retrospective Analysis of the Brigham and Women’s Rheumatoid Arthritis Sequential Study Registry

    Nancy A. Shadick1, Michael E Weinblatt1, Christine K Iannaccone2, Michelle Frits3, Tigwa Davis4, Christopher Young4, David H. Collier5, Mahdi Gharaibeh5 and Bradley S. Stolshek6, 1Brigham and Women's Hospital, Boston, MA, 2Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, 3Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, 4Health Analytics, LLC, Columbia, MD, 5Amgen Inc., Thousand Oaks, CA, 6Amgen, Inc., Thousand Oaks, CA

    Background/Purpose: Biologics in combination with methotrexate (MTX) are being incorporated earlier in rheumatoid arthritis (RA) therapy to prevent long-term damage and maintain patient function. While…
  • Abstract Number: 929 • 2018 ACR/ARHP Annual Meeting

    Transcriptional Profiling of the Subcutaneous Rheumatoid Nodule: An Insight into Pathogenic Mechanisms and Cellular Content

    Judith Marsman1, Melanie J Millier1, John Highton1, Lisa K. Stamp2 and Paul A Hessian1, 1Department of Medicine, University of Otago, Dunedin, New Zealand, 2University of Otago, Christchurch, New Zealand

    Background/Purpose: Rheumatoid nodules are the most common cutaneous manifestation in patients with RA, often associated with longstanding and a more severe disease course. Paradoxically, therapy…
  • Abstract Number: 2822 • 2018 ACR/ARHP Annual Meeting

    Should We Prefer Leflunomide to Methotrexate in Combination with Biologics? a Systematic Review and a Meta-Analysis

    Guillaume Decarriere1, Thomas Barnetche2, Cédric Lukas3, Cécile Gaujoux-Viala4, Bernard Combe5, Jacques Morel6 and Claire I. Daien7, 1Department of Rheumatology, CHU Lapeyronie, Montpellier, France, 2Rheumatology Department, FHU ACRONIM, Bordeaux University Hospital, Bordeaux, France, 3Rheumatology, CHU Lapeyronie and EA2415, Montpellier University, University of Montpellier, France, 4Rheumatology, Nîmes University Hospital and EA2415 Montpellier University, Nîmes, France, 5Rheumatology, University Hospital Lapeyronie, Montpellier, Montpellier, France, 6Department of Rheumatology, University Hospital Lapeyronie, Montpellier, Montpellier, France, 7Department of rheumatology, Lapeyronie Hospital and Montpellier University, Montpellier, France

    Background/Purpose: In rheumatoid arthritis (RA), biologics are more efficient in combination with methotrexate (MTX) than in monotherapy. When MTX cannot be used, others csDMARD can…
  • Abstract Number: 1445 • 2017 ACR/ARHP Annual Meeting

    Effect of Methotrexate (MTX), and MTX Plus Colchicine (CCH) on the Expression and Activity of NLRP3 Inflammasome in Patients with Early Rheumatoid Arthritis (RA)

    Dolores Ramos-Bello1, Crisol Alvarez-Quiroga2, Georgina Aguilera Barragán-Pickens3, Angel Javier Pedro Martínez3, Tania Adriana Luna-Zúñiga3, Georgina Martínez-Flores3, Eduardo Saul Acevedo-Castañeda4, Homero López-Ferretis3, Enrique Cuevas-Orta3, Eva Santillan-Guerrero3, Ricardo Moreno-Valdez3, Martín Saldaña-Baarnard3, Marco Ulises Martinez-Martinez5, David Herrera Van Oostdam6, Roberto González-Amaro7 and Carlos Abud-Mendoza8, 1Reumatología, Unidad Regional de Reumatologia y Osteoporosis Hospital Central "Dr. Ignacio Morones Prieto" y Facultad de Medicina de la UASLP, San Luis Potosi, Mexico, 2División de Medicina Molecular y Traslacional, Centro de Investigación en Ciencias de la Salud y Biomedicina, UASLP, San Luis Potosí, Mexico, 3Unidad Regional de Reumatologia y Osteoporosis Hospital Central "Dr. Ignacio Morones Prieto" y Facultad de Medicina de la UASLP, San Luis Potosí, Mexico, 4Medicina Interna, Unidad Regional de Reumatologia y Osteoporosis Hospital Central "Dr. Ignacio Morones Prieto" y Facultad de Medicina de la UASLP, San Luis Potosí, Mexico, 5Unidad de Investigaciones Reumatológicas, Faculty of Medicine, Universidad Autónoma de San Luis Potosí and Hospital Central, San Luis Potosí, Mexico, 6Unidad de Investigaciones Reumatológicas, Hospital Central & Facultad de Medicina, Universidad Autónoma de San Luis Potosí, San Luis Potosí, Mexico, 7Inmunología, Facultad de Medicina de la UASLP, San Luis Potosí, Mexico, 8Unidad de Investigaciones Reumatológicas y Osteoporosis, Faculty of Medicine, Universidad Autónoma de San Luis Potosí and Hospital Central, San Luis Potosí, Mexico

    Background/Purpose: NLRP3 inflammasome is an intracellular protein complex involved in the production of pro-inflammatory cytokines as IL-1β and IL-18, which has been reported to have…
  • Abstract Number: 2535 • 2016 ACR/ARHP Annual Meeting

    Effect of Methotrexate in the Presence of Drug and the Appearance of Antibodies Against Tumour Necrosis Factor Inhibitors in Patients with Rheumatoid Arthritis

    Chamaida Plasencia-Rodriguez1, Ana Martínez2, Alejandro Villalba3, Teresa Jurado4, Eva Olariaga-Merida5, Araceli Mezcua6, Diana Peiteado3, Gema Bonilla3, Laura Nuño3, Alejandro Balsa1 and Dora Pascual-Salcedo2, 1Instituto de Investigación Hospital Universitario La Paz (IDIPAZ), Madrid, Spain, 2Immunology Unit, La Paz University Hospital-Immunology, Madrid, Spain, 3Rheumatology, Hospital La Paz - IdiPaz, Madrid, Spain, 4Immunology Unit, La Paz University Hospital-IdiPaz, MADRID, Spain, 5Immunology, University Hospital La Paz, Madrid, Spain, 6Immunology Unit, La Paz University Hospital, Madrid, Spain

    Background/Purpose: Several factors influence pharmacokinetics of TNFinhibitors (TNFi). One relevant factor is the formation of anti drug- antibodies (ADA) associated with low drug levels and…
  • Abstract Number: 611 • 2015 ACR/ARHP Annual Meeting

    The Rapid Kinetics of Optimal Treatment with Subcutaneous Methotrexate in Early Inflammatory Arthritis

    Anna O'Connor1, J Carter Thorne2, Diane Tin3 and Janet E. Pope4, 1Schulich School of Medicine and Dentistry, University of Western Ontario, London, ON, Canada, 2University of Toronto, Toronto, ON, Canada, 3The Arthritis Program, Southlake Regional Health Centre, Newmarket, ON, Canada, 4Monsignor Roney Bldg/Rheum, University of Western Ontario, St Joseph Health Care, London, ON, Canada

    Background/Purpose: Methotrexate (MTX) is standard treatment in RA. Absorption is better in subcutaneous MTX (scMTX), which may impact speed of onset. In RA, earlier time…
  • Abstract Number: 1659 • 2015 ACR/ARHP Annual Meeting

    Lack of Effect of Reduced Folic Acid Supplementation on Disease Activity in RA

    Lisa K. Stamp1, Jill Drake2, John L. O'Donnell3, Christopher Frampton4 and Peter T. Chapman5, 1Medicine, University of Otago, Christchurch, Christchurch, New Zealand, 2Rheumatology, Immunology and Allergy, Christchurch Hospital, Christchurch, New Zealand, 3Immunology, Canterbury Health Laboratories, Christchurch, New Zealand, 4University of Otago, Christchurch, Christchurch, New Zealand, 5Rheumatology, Christchurch Hospital, Christchurch, New Zealand

    Background/Purpose: It is recommended that all patients receiving MTX also receive at least 5mg/week of folic acid in an effort to reduce occurrence of MTX…
  • Abstract Number: 1665 • 2015 ACR/ARHP Annual Meeting

    Treatment Patterns in Rheumatoid Arthritis after Methotrexate: Data from a Rheumatoid Arthritis Cohort

    Janet E. Pope1, Mohammad Movahedi2,3, Angela Cesta2, Xiuying Li2, Sandra Couto2, Emmanouil Rampakakis3, John S. Sampalis3,4, Claire Bombardier2,5,6 and OBRI Investigators, 1University of Western Ontario, London, ON, Canada, 2Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada, 3JSS Medical Research, St-Laurent, QC, Canada, 4McGill University, Montreal, QC, Canada, 5University of Toronto, Department of Medicine (DOM) and Institute of Health Policy Management, and Evaluation (IHPME), Toronto, ON, Canada, 6Division of Rheumatology, Mount Sinai Hospital, Toronto, ON, Canada

    Background/Purpose: Guidelines support the use of combination conventional synthetic Disease-Modifying Antirheumatic Drugs (csDMARDs), switching csDMARDs and/or use of biologic DMARDs (bDMARDs) treatment in active rheumatoid…
  • Abstract Number: 2223 • 2013 ACR/ARHP Annual Meeting

    Monitoring Of Active Matrix Metalloproteinase-3 Using

    Sung Jae Choi1, Young Ho Seo2, Young Ho Lee3, Jong Dae Ji1, Gwan Gyu Song4, Aeju Lee2 and Jae-Hoon Kim4, 1Rheumatology, Korea University Medical Center, Seoul, South Korea, 2Rheumatology, Korea University Medical center, Seoul, South Korea, 3Internal Medicine, Rheumatology, Korea University Medical Center, Seoul, South Korea, 4Div of Rheum, Dept of Int Med, Korea Univ College of Med, Seoul, South Korea

    Background/Purpose: Active matrix metalloproteinase-3 (MMP-3) is a prognostic marker of rheumatoid arthritis (RA). Recently, we developed the MMP-3 probe which can specifically detect an active…
  • Abstract Number: 1337 • 2013 ACR/ARHP Annual Meeting

    Nearly Pain Free Self-Administration Of Methotrexate Using An Investigational Auto-Injector: Results Of a Phase-2 Clinical Trial In Rheumatoid Arthritis Patients With Mild-To-Severe Functional Limitations

    Alan J. Kivitz1, David McLain2, John Hill3, Bruce Freundlich4, Jonathan Jaffe5 and Kaushik J. Dave6, 1Altoona Center for Clinical Research, Duncansville, PA, 2Rheumatology, McLain Medical Associates, PC, Birmingham, AL, 3Avail Clinical Research, DeLand, FL, 4University of Pennsylvania, Philadelphia, PA, 5Clinical Development, Antares Pharma Inc, Ewing, NJ, 6Product Development, Antares Pharma Inc, Ewing, NJ

    Background/Purpose: Methotrexate (MTX) is the cornerstone of rheumatoid arthritis (RA) treatment. Limitations of systemic exposure of oral MTX can affect its efficacy. Subcutaneous (SC) MTX…
  • Abstract Number: 796 • 2013 ACR/ARHP Annual Meeting

    Drug Exposure Limitations of Oral Methotrexate (MTX) At Doses >15mgs May be Overcome By Using a Subcutaneous MTX Auto-Injector in Patients With Rheumatoid Arthritis (RA)

    Michael H. Schiff1, Lee S. Simon2, Bruce Freundlich3, Jonathan Jaffe4 and Kaushik J. Dave5, 1Rheumatology Division, University of Colorado, Denver, CO, 2SDG LLC Consulting, West Newton, MA, 3University of Pennsylvania, Philadelphia, PA, 4Clinical Development, Antares Pharma Inc, Ewing, NJ, 5Product Development, Antares Pharma Inc, Ewing, NJ

    Drug exposure limitations of oral methotrexate (MTX) at doses >15mgs may be overcome by using a subcutaneous MTX auto-injector in pts with rheumatoid arthritis (RA) Background/Purpose:…
  • Abstract Number: 2313 • 2013 ACR/ARHP Annual Meeting

    Pain-Related Anxiety As a Barrier To Use Of Methotrexate In Rheumatoid Arthritis: Comparing Conventional Vial, Needles, and Syringe With An Investigational Auto-Injector In Healthy Volunteers

    Victoria L. Ruffing1 and Kaushik J. Dave2, 1Medicine JHAAC, Johns Hopkins University, Baltimore, MD, 2Product Development, Antares Pharma Inc, Ewing, NJ

    Background/Purpose:  Methotrexate (MTX) is the cornerstone of rheumatoid arthritis (RA) treatment. Limitations of systemic exposure of oral MTX can affect its efficacy. Subcutaneous (SC) MTX…
  • Abstract Number: 2324 • 2013 ACR/ARHP Annual Meeting

    Persistence On Biologics Is Associated With Concomitant Methotrexate Use Among Rheumatoid Arthritis Patient

    Jie Zhang1, Fenglong Xie2, Elizabeth S. Delzell3, Huifeng Yun3, James Lewis4, Kevin Haynes5, Lang Chen6 and Jeffrey R. Curtis7, 1Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, 2Rheumatology & Immunology, University of Alabama at Birmingham, Birmingham, AL, 3Epidemiology, University of Alabama at Birmingham, Birmingham, AL, 4Medicine, University of Pennsylvania, Philadelphia, PA, 5Clinical Epidemiology and Biostatistics, University of Pennsylvania., Philadelphia, PA, 6Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, 7University of Alabama at Birmingham, Birmingham, AL

    Persistence on Biologics is Associated with Concomitant Methotrexate Use among Rheumatoid Arthritis Patient Background/Purpose: Concomitant methotrexate (MTX) is associated with improved treatment efficacy in randomized controlled…
  • Abstract Number: 1322 • 2012 ACR/ARHP Annual Meeting

    Coadministration of ASP015K, a Novel Janus Kinase Inhibitor with Methotrexate Demonstrates Tolerability and Lack of Pharmacokinetic Interactions in Patients with Rheumatoid Arthritis

    Tong Zhu1, Kazuo Oda2, Udaya Valluri1, Bogie Moore1, Ying Cao1, Vishala Chindalore3 and Bola Akinlade4, 1Astellas Pharma Global Development, Inc., Northbrook, IL, 2Drug Metabolism Research Labs. Drug Discovery Research, Astellas Pharma Inc., Osaka, Japan, 3Pinnacle Research Group/Anniston Medical Clinic, Anniston, AL, 4Immunology Development, Astellas Pharma Global Development, Inc., Northbrook, IL

    Background/Purpose: ASP015K is an oral Janus kinase (JAK) inhibitor with selectivity for JAK1/3 in development for treatment of rheumatoid arthritis (RA) and other autoimmune diseases.…
  • Abstract Number: 996 • 2012 ACR/ARHP Annual Meeting

    Genetic Predictors of Methotrexate Efficacy and Toxicity in Early Rheumatoid Arthritis: Results From the Treatment of Early Aggressive Rheumatoid Arthritis Trial

    Stella Aslibekyan1, Elizabeth Brown2, Richard J. Reynolds3, David T. Redden4, Sarah L. Morgan5, Joseph Baggott1, Jin Sha1, Larry W. Moreland6, James R. O'Dell7, Jeffrey R. Curtis8, S. Louis Bridges Jr.9 and Donna K. Arnett1, 1University of Alabama at Birmingham, Birmingham, AL, 2Univ of Alabama at Birmingham, Birmingham, AL, Birmingham, AL, 3Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, 4Biostatistics, University of Alabama at Birmingham, Birmingham, AL, 5University of Alabama Birmingham, Birmingham, AL, 6Division of Rheumatology & Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, 7Dept of Internal Medicine, Univ of Nebraska Med Ctr, Omaha, NE, 8Rheumatology & Immunology, Univ of Alabama-Birmingham, Birmingham, AL, 9Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL

    Background/Purpose: Methotrexate (MTX) has emerged as first-line therapy for early moderate to severe rheumatoid arthritis (RA), but individual variation in treatment efficacy and toxicity remains…
  • 1
  • 2
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology